# Most-Favored-Nation Drug Pricing Deals The Trump administration's 2025–2026 campaign of bilateral, voluntary, largely confidential pricing agreements with major drugmakers, culminating in the **TrumpRx.gov** platform. The deals are the administration's answer to drug-price populism — and this vault's premier specimen of **deal theater**: presidentially branded, tariff-coerced, structurally shallow, and politically potent. ## Timeline - **May 12, 2025** — Trump signs the most-favored-nation executive order, demanding U.S. prices match the lowest paid in comparable developed nations. - **July 31, 2025** — Letters to seventeen major manufacturers setting four demands (MFN pricing for Medicaid, MFN launch pricing on new drugs, direct-to-consumer discounts, repatriated manufacturing). - **September 30, 2025** — [[Pfizer]] signs the first deal: Medicaid MFN, ~50% average DTC discounts, $70B U.S. investment — for a three-year exemption from the 100% [[Section 232]] pharmaceutical tariffs. - **November 6, 2025** — The GLP-1 deals with [[Eli Lilly]] and [[Novo Nordisk]]: $245/month for Medicare/Medicaid, ~$346/month via TrumpRx for tirzepatide products, MFN pledges on new launches. - **December 19, 2025** — Nine more sign: Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Genentech, Gilead, GSK, Merck, Novartis, and [[Sanofi]]. - **February 5, 2026** — TrumpRx.gov launches, fronted by Trump, [[Mehmet Oz]], and National Design Studio chief Joe Gebbia, with drugs from the first five signatories (AstraZeneca, Lilly, EMD Serono, Novo Nordisk, Pfizer). The site sells nothing — it is a referral portal to manufacturers' own DTC storefronts. ## The Mechanism The leverage is tariffs: Section 232 pharmaceutical import tariffs set at 100% for non-compliant companies, waived or deferred for signatories. Foreign manufacturers ([[Novo Nordisk]], [[Sanofi]], AstraZeneca, GSK, Novartis) had the most direct exposure, which is why the cohort skews European. What companies bought, in effect, was tariff insurance priced in discount announcements. ## What It Is and Isn't The deals deliver real discounts on *selected* drugs through *selected* channels — cash-pay DTC and Medicaid — while leaving untouched the structures that set what most Americans actually pay: [[Pharmacy Benefit Managers]] rebate games, patent thickets, launch prices, and employer-plan negotiations. Terms are confidential and unverifiable against net prices; participation, pricing, and duration exist at presidential discretion rather than in statute. Contrast the [[Inflation Reduction Act]]'s negotiation authority — slower, narrower, but written into law and survivable across administrations, which is precisely why [[PhRMA]] litigates against the IRA while its members line up for MFN deals. The branding tells the story: drug pricing reconstituted as a personal gift from the president — see [[Big Pharma]] for the products-vs-power frame this fits inside. ## Watch For - Whether MFN deals get cited to justify weakening or non-enforcement of IRA negotiation rounds - TrumpRx referral data and whether claimed average discounts survive independent audit - Post-Trump durability: confidential voluntary deals have no statutory afterlife - Midterm messaging: TrumpRx as the GOP's answer to Democratic drug-pricing attacks ## Connections - [[Donald Trump]] — Brand and leverage - [[Mehmet Oz]] — CMS administrator fronting the platform - [[Pfizer]] / [[Eli Lilly]] / [[Novo Nordisk]] / [[Sanofi]] — Profiled signatories - [[PhRMA]] — Litigates the IRA, accommodates the deals - [[Big Pharma]] — Hub analysis - [[Inflation Reduction Act]] — The structural-reform contrast